edoxaban vs rivaroxaban
Side-by-side comparison of edoxaban and rivaroxaban Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Savaysa
Xarelto
Savaysa is a medicine that helps to prevent blood clots. It is used to lower the chance of stroke in people with an irregular heartbeat (atrial fibrillation) and to treat blood clots in the legs or lungs.
Rivaroxaban (Xarelto) is a drug that helps to prevent blood clots from forming. It is used to lower the risk of stroke and treat or prevent dangerous clots in your veins and lungs.
Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat. It is also used to treat blood clots in the deep veins of your legs (DVT) or in your lungs (PE). You will likely need to take another medicine to prevent blood clots for 5 to 10 days before starting Savaysa for DVT or PE.
This medicine can help prevent strokes in people with an irregular heartbeat called atrial fibrillation. It also treats blood clots in the legs (deep vein thrombosis or DVT) and lungs (pulmonary embolism or PE). Rivaroxaban can also lower the risk of these clots coming back. It is also used to prevent blood clots after hip or knee replacement surgery and in acutely ill patients.
Savaysa is a factor Xa inhibitor. This means it blocks a substance in your blood called factor Xa. By blocking factor Xa, Savaysa helps to prevent blood from clotting.
Rivaroxaban is a factor Xa inhibitor. It blocks a substance in your blood called factor Xa. By blocking factor Xa, the medicine helps to prevent blood clots from forming.
- • Bleeding
- • Anemia (low red blood cells)
- • Rash
- • Abnormal liver function tests
- • Bleeding
- • Cough
- • Vomiting
- • Gastroenteritis (inflammation of the stomach and intestines)
No adverse event reports.
- Bleeding in the stomach or intestines 21,559
- Using the medicine for something it's not approved for 7,808
- Bleeding 7,713
- Shortness of breath 7,149
- Nosebleed 6,698
Savaysa may not work as well to prevent strokes if you have atrial fibrillation and your kidneys are working very well (CrCl > 95 mL/min). If you stop taking Savaysa too soon, you have a higher risk of blood clots or stroke. If you get medicine injected into your spine while taking Savaysa, it could cause bleeding around your spine, which can lead to paralysis.
This medicine has two important warnings. First, stopping this medicine too early can increase your risk of blood clots. Do not stop taking it without talking to your doctor first. Second, if you receive spinal anesthesia or have a spinal puncture while taking this medicine, you have a risk of a blood clot forming around your spine, which can cause long-term paralysis.
Tell your doctor if you are pregnant or plan to become pregnant. Savaysa may increase the risk of bleeding in the fetus. Do not breastfeed while taking Savaysa.
Talk to your doctor if you are pregnant or plan to become pregnant. This medicine may cause bleeding problems during pregnancy and delivery. It is not known if this medicine passes into breast milk, so talk to your doctor about the risks and benefits of breastfeeding.
Also Compare — Nearby Drugs
Compare edoxaban with
Compare rivaroxaban with
How to Read This edoxaban vs rivaroxaban Comparison
edoxaban is classified in the Direct Oral Anticoagulant (Factor Xa Inhibitor) drug class, while rivaroxaban sits within the Direct Oral Anticoagulant (Factor Xa Inhibitor) class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, edoxaban has 0 submissions while rivaroxaban has 50,927. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between edoxaban and rivaroxaban — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.